NCT06848881 Cryoablation vs Thoracoscopic Surgery for GGN
| NCT ID | NCT06848881 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | Ground-Glass Opacity |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-04-20 |
| Primary Completion | 2030-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-04-20 with a primary completion date of 2030-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to investigate the efficacy and safety of Cryoablation and Thoracoscopic Surgery in the treatment of pulmonary ground-glass nodules.
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥ 18 years old. 2. The size of the GGN is 8-20mm (with less than 25% solid component), and the number of nodules requiring treatment in the short term is less than 3. 3. Pathological confirmation of the GGN as non-small cell lung cancer; or progression of the GGN during at least 3 months of follow-up, including enlargement of the largest diameter, increase in solid component, or the appearance of a significant solid component in a previously pure GGN, with multidisciplinary discussion (including radiology, thoracic surgery, and pulmonology) suggesting malignancy. 4. No lymph node, pulmonary, or distant metastasis to other organs. 5. After multidisciplinary evaluation, the patient is considered capable of tolerating both surgical and ablation procedures. 6. Unsuitable for radiation therapy or refusal of radiation therapy. 7. Willing to participate in this clinical study and sign the informed consent form. Exclusion Criteria: 1. Patients in poor general condition, with ECOG physical fitness score \>2, unable to tolerate surgery or ablation therapy, or with relevant contraindications. 2. Patients who have previously received other treatments for pulmonary GGNs. 3. Patients with poor compliance. 4. Severe heart, lung, kidney, brain, or other vital organ diseases. 5. Active bacterial or fungal infections. 6. Simultaneous or metachronous (within the past 5 years) double cancers. 7. Women during pregnancy or breast-feeding. 8. History of radiation therapy. 9. Bleeding tendency, abnormal coagulation functions, or coagulation disorders that cannot be corrected after treatment. 10. Contraindications to general anesthesia. 11. Expected survival time \< 6 months. 12. The researcher believes that it is not suitable for inclusion.
Contact & Investigator
Jiayuan Sun, MD, PhD
STUDY DIRECTOR
Shanghai Chest Hospital
Frequently Asked Questions
Who can join the NCT06848881 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ground-Glass Opacity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06848881 currently recruiting?
Yes, NCT06848881 is actively recruiting participants. Contact the research team at xkyyjysun@163.com for enrollment information.
Where is the NCT06848881 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06848881 clinical trial?
NCT06848881 is sponsored by Shanghai Chest Hospital. The principal investigator is Jiayuan Sun, MD, PhD at Shanghai Chest Hospital. The trial plans to enroll 160 participants.